Myomo vs Trisalus Life Sciences
Myomo and Trisalus Life Sciences are similar in size: $40.9m and $45.2m of revenue in their latest fiscal years. Trisalus Life Sciences grew faster (53.4% against 25.7%). Myomo kept more of each dollar of sales as profit: a net margin of -38.1% against -86.9%.
| Latest fiscal year | MyomoMYO, 2025 | Trisalus Life SciencesTLSI, 2025 |
|---|---|---|
| Revenue | $40.9m | $45.2m |
| Revenue growth | 25.7% | 53.4% |
| Net income | −$15.6m | −$39.2m |
| Operating margin | -35.2% | -59.7% |
| Net margin | -38.1% | -86.9% |
| Return on equity | -86.2% | — |
| Free cash flow | −$16.3m | −$18.9m |
| Cash | $14.1m | $20.4m |
| Total debt | $12.5m | $33.0m |
| Debt to equity | 109.9% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 102 |
| Market value | $50.6m | $213m |
| Price vs our value range | — | — |
| Moat score | 33 (Weak) | — |
| Insider trades, 12 months | 13 buys, 8 sales | 12 buys, 18 sales |